Extended Data Fig. 1: Isolation of monocytes and manufacturing of the MATCH01 product.
From: Autologous macrophage therapy for liver cirrhosis: a phase 2 open-label randomized controlled trial
a-d, Process robustness for manufacturing of the MATCH01 product. All products manufactured in the 23-participant single-dose group and the 3-participant triple-dose group. a-b Leukapheresis starting material (a, Total Nucleated Cell (TNC) collected from steady state leukapheresis from male and female participants * p = 0.0398; b, CD14+ monocyte content in steady state leukapheresis ** p = 0.0069). Two-sided unpaired t-test. c-d, Performance in manufacturing process (c, yield of CD14+ cells from the CliniMACS Prodigy selection procedure; d, final process yield of manufactured product for infusion, as a percentage of input CD14+ monocytes. ns = no significant difference by two-sided unpaired t-test. e-f, Phenotype of macrophages in final manufactured product for infusion, compared between alcohol and non-alcohol-related liver disease groups, 19 consecutive participants from single dose series. Two-sided unpaired t-tests. e, Expression of CD14 and CD16 in infused product between alcohol and non-alcohol-related liver disease groups. f, Change in relative expression of CD163, CD169 and CCR2 molecules on final product macrophages, compared to input monocytes. In all panels, bars represent group means.
